|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Greatbatch, Inc. (NYSE:GB), a manufacturer of critical components used in implantable medical devices and other technically demanding applications. |
|---|---|
| Transferring Party | Enpath Medical, Inc. (Nasdaq:NPTH), a manufacturer of disposable medical device products for the cardiac rhythm management (CRM), neuromodulation and interventional radiology markets. |
| Sector | Medical Devices |
| Date | June 18, 2007 |
| Analysis Expands GB's product offerings to CRM and broadens its reach into the vascular segment with a core introducer product line, while adding several major new OEM customers and a strong management and regulatory team. Supports GB's long-term objective of customer and market diversification. Deal value -- $102m, on '06 sales of $37m (2.7x) and operating profit of $2m (51x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |